Pasar al contenido principal

VACUNAS BIVALENTES DIVA FRENTE A LOS VIRUS DE LA ENFERMEDAD HEMORRAGICA EPIZOOTICA Y DE LA LENGUA AZUL BASADAS EN VECTORES VIRALES VACCINIA ANKARA MODIFICADOS BICISTRONICOS

PID2023-147304OR-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The MVA-VP2-NS1-2A-NS2-Nt vaccine candidate provides heterologous protection in sheep against bluetongue virus

  • Jiménez-Cabello, L.
  • Utrilla-Trigo, S.
  • Illescas-Amo, M.
  • Rodríguez-Sanando, K.
  • Benavides, Julio
  • Calvo-Pinilla, E.
  • Ortego, J.
12 páginas, 6 figuras, 1 tabla., Bluetongue (BT) is an important arthropod-borne livestock disease transmitted by Culicoides midges. The etiological agent, Bluetongue virus (BTV), can lead to severe economic losses due to reduced productivity and trade restrictions. Nowadays, classical vaccines based on inactivated viruses are used to control outbreaks but do not confer multiserotype protection, which reinforces the idea of pursuing research into developing strategies that enhance the immune response directed to conserved antigenic regions, aiming broader protection across multiple serotypes. Recently, we described a vaccine candidate that confers full protection against a homologous serotype of BTV based on recombinant Modified Vaccinia Virus Ankara (MVA) co-expressing the highly conserved BTV nonstructural protein NS1 and the N-terminal end of NS2 along with protein VP2 of BTV-4. In this work, we evaluated the multiserotype protective capacity of this recombinant vaccine candidate in sheep after infection with the heterologous virus BTV-8, achieving a significant blockade of viral replication and attenuation of the clinical signs induced by BTV. After infection, vaccinated animals showed more regulated pro-inflammatory cytokine levels compared to non-vaccinated sheep. In addition, we noticed the induction of potent T cell immune responses specific to NS1 and NS2-Nt proteins of BTV, mainly based on CD8+ T cells, which could mediate the protection against BTV-8. Moreover, stimulated immunized sheep PBMCs with BTV antigens triggered the secretion of IL-6, IL-1β, IL-1α, IL-17a, IL-10 and IFN-γ, cytokines that play crucial roles in initiating immune responses., The author(s) declare that financial support was received for the research and/or publication of this article. The work was supported by grants PID2020-112992RR-I00 and PID2023-147304OR-I00 funded by MCIN/AEI/10.13039/501100011033, as well as grant 101136346 European Partnership Animal health and Welfare (EUPAHW). SU-T. and LJ-C. were granted by FPI SGIT 2018 and PRE2021 097320 funded by MCIN/AEI/10.13039/ 501100011033 and by “ESF Investing in your future”, respectively, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rapid Quantification of Bluetongue Virus-Neutralizing Antibodies Using Bioluminescent Reporter-Expressing Viruses

  • Jiménez-Cabello, L.
  • Utrilla-Trigo, S.
  • Calvo Pinilla, Eva María
  • Nogales, Aitor
  • Ortego, Javier
This article belongs to the Special Issue Immunization Strategies for Animal Health., Bluetongue virus (BTV) is the causative agent of the significant livestock disease Bluetongue (BT), which causes severe economic losses associated with its considerable impact on the health and trade of ruminants., [Background/Objectives:] BTV infection and vaccination against the virus typically result in the induction of antibodies with the capacity to neutralize viral infection. Classic neutralization approaches resemble the methodology applied for neutralizing antibodies (NAbs) quantification. To improve long-standing and new-generation methodologies for the quantification of NAbs or evaluation of antivirals, we offer here the development of a new luciferase-based microneutralization approach as a proof-of-concept., [Methods:] Central to this innovative approach is the recently generated set of replication-competent reporter-expressing recombinant BTV, where the NanoLuc luciferase protein expression serves as a quantifiable readout for viral replication. After evaluating a set of heat-inactivated serum samples with neutralizing activity (measured via SNTs), these were incubated with 100 PFU of NLuc-expressing rBTV of serotype 1, 4 or 8 and Vero cells were infected with the serum–virus mixture. Then, the luminescent signal was measured at 48 h post-infection., [Results:] Using the proposed NLuc-based assay and the luminescent signal in the supernatant, we could detect neutralizing activity as soon as 48 h post-infection. Importantly, we were able to observe a strong correlation between NAbs titers measured by classic microneutralization assay and by our bioluminescent approach (BTV-1 Spearman r = 0.932901; p-value < 0.0001; BTV-4 Spearman r = 0.8070192; p-value < 0.0001; BTV-8 Spearman r = 0.9983; p-value < 0.0001). In addition, the NLuc-based assay displayed a serotype-specific character potentially equivalent to classic SNT methods., [Conclusions:] In summary, our reporter-based microneutralization assay provides a rapid and suitable method to quantify BTV-neutralizing antibodies in serum samples of natural hosts after vaccination or infection, with a serotype-specificity equivalent to classic SNT methods., The work was supported by grants PID2020-112992RR-I00 and PID2023-147304OR-I00 funded by MCIN/AEI/10.13039/501100011033, as well as grant 101136346 European Partnership Animal health and Welfare (EUPAHW). L.J.-C. was provided with the grant PRE2021 097320 funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”., Peer reviewed